Chronic venous disease (CVD) represents a significant healthcare burden. Thrombophilia is proposed as a risk factor, particularly for post-thrombotic CVD. A systematic review was performed to determine the relationship between thrombophilia and non-thrombotic CVD. MEDLINE â and Embase â databases were searched from 1946 up to March 2018. Case-control studies, cohort studies or randomised clinical trials reporting on thrombophilias in non-thrombotic lower limb CVD in adult patients were included. Non-English and post-thrombotic syndrome studies were excluded. Study selection and data extraction were performed by two reviewers. Fifteen studies were included, reporting on 916 cases and 1261 controls. Studies largely focused on venous ulceration and investigated multiple haemostatic factors. An association between thrombophilia and non-thrombotic CVD was identified, with greater prevalence and factor concentration alteration reported in patients compared to controls. Concomitant thrombophilia presence was associated with earlier CVD onset. Relationship strength varied, with commoner aetiologies showing clearer correlation than rarer ones. Thrombophilia is associated with non-thrombotic CVD but the mechanism is unclear and causation cannot be determined. Future research should focus on prospective studies with larger populations and identify adjunct therapies targeting thrombophilia.
Chronic venous disease (CVD) represents a significant economic burden in developed countries, with 1-2% of the annual healthcare budget spent on venous ulcer care alone (Laing, 1992; Rabe & Pannier, 2010) . Clinical signs are grouped into seven categories with progressive severity from C0 to C6 (Table I) (Eklof et al, 2004) . Classes C0, C1, C2 and C3 describe no clinical signs, telangiectasia, varicose veins (VV) and oedema respectively. Classes C4, C5 and C6 disease describe trophic skin changes and, ultimately, venous ulceration. Reported prevalence rates are heterogeneous: VV affect 2-56% of men and <1 to 73% of women; C4-6 disease affects between <1% and 17% of males and <1% and 40% of females (Beebe-Dimmer et al, 2005) .
Numerous risk factors have been established, including increased age, obesity and family history (Table II) . Increasingly, thrombophilia, defined as 'any alteration of the coagulation pathways that predisposes to thrombosis' (Mitchell, 2010) , has been suggested as a risk factor. Thrombophilias are divided into genetic or acquired disorders (Table III) . Studies on thrombophilias in CVD patients have reported deranged levels or mutations in pro- (Brandt et al, 2009; Criado et al, 2014) and anti-thrombotic factors (Tsutsui et al, 1997; Brandt et al, 2009 ) as well as fibrinolytic mediators. While venous wall dysfunction may occur following macrovascular thrombosis (i.e. post-thrombotic syndrome), CVD can also develop in its absence. The following theories are therefore of more interest with regards to non-thrombotic CVD.
In the fibrin cuff theory, cuffs containing extracellular matrix proteins, such as collagen, fibronectin and fibrin (Herrick et al, 1992) , form around capillaries. These cuffs trap growth factors (Falanga & Eaglstein, 1993) and are suspected to prevent effective diffusion of nutrients into the skin (Browse & Burnand, 1982) . This leads to both trophic skin changes and ulceration from epidermal cell death. Venous endothelial cells also exhibit metabolic activation, suggesting that oedema may be from transendothelial transport and channels allowing fluid and macromolecule efflux (Pappas et al, 1997) . The microvascular thrombosis theory proposes that recurrent microthrombi occlude capillaries and decrease skin perfusion. This chronic damage may lead to both CVD development and poorly healing chronic venous ulceration (CVU).
While current evidence is unable to show a definitive link, these microangiopathic changes may be associated with the macrovascular manifestations seen in CVD. Most agree that valvular incompetence is a key finding (Bergan et al, 2006) but there remains debate on the initiating event, which can be summarised by the descending and ascending theories.
The descending theory suggests that primary valvular incompetence causes vein wall dilatation, causing CVD progression in a proximal to distal fashion (Ludbrook, 1963; Onida, 2017) (Fig 1A) . Conversely, the ascending theory describes primary vein wall dysfunction from dysregulated collagen and elastin (Sansilvestri-Morel et al, 2003) , leading to vein wall dilatation and subsequent valve leaflet separation and development of valvular incompetence (Bernardini et al, 2010; Onida, 2017) (Fig 1B) . Both lead to blood flow disturbances in the superficial and/or deep venous systems. The resultant venous hypertension leads to intraendothelial pore enlargement (Pappenheimer, 1953) , protein exudation and pericapillary accumulation of fluid, manifesting as oedema. Protein leakage triggers an inflammatory response, presenting clinically as eczema, dermatitis and lipodermatosclerosis, and may contribute to the development of the fibrin cuff. Skin pigmentation from ferritin and haemosiderin deposition follows extravascular red blood cell breakdown (Bergan et al, 2006) , with microvascular occlusion by microthrombi leading to poor healing and worsening CVD.
Non-thrombotic CVD may therefore develop in the context of thrombophilia following microvascular thrombosis and pericapillary fibrin cuff development, with alterations in the pro-and anti-coagulation factors leading to dysregulation of thrombosis and fibrinolysis. These subtle changes to the superficial venous system may go unnoticed by clinicians and contribute to venous dilatation and valvular incompetence, allowing for CVD progression to more severe stages.
To the authors' knowledge, the relationship between thrombophilias and non-thrombotic CVD has not been elucidated. This study aims to provide readers with a systematic review on the subject and with recommendations for clinical practice and future research.
Materials and methods

Search strategy
A systematic review was performed in accordance to the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) guidelines (Liberati et al, 2009) . MEDLINE â and Embase â databases were searched from Table II . Established and potential risk factors of CVD.
Risk factor Risk
Age 6% increase in risk of complicated CVD with each year of age (Scott et al, 1995) Family history VV patients are 21Á5 times more likely to have a positive family history but family history is not a significant factor for complicated CVD (Scott et al, 1995 ) Pregnancy VV prevalence shown to be increased with parity (Laurikka et al, 2002 ) Obesity BMI shown to be a risk factor for VV in females but not males (Evans et al, 1999) Smoking VV are associated with higher smoking rates in studies, including the Framingham Study (Brand et al, 1988) Relationship not found in other studies, including the Edinburgh Vein Study (Komsuoglu et al, 1994; Evans et al, 1999) 
Standing occupation
Orthostasis has been reported to increase incidence of VV but other studies have shown no association (Maffei et al, 1986; Brand et al, 1988) BMI, body mass index; CVD, chronic venous disorders; VV, varicose veins. 
Inclusion and exclusion criteria
Case-control studies, cohort studies or randomised clinical trials (RCTs) reported in English investigating thrombophilias in adult patients with non-thrombotic lower limb CVD were included. Studies on post-thrombotic syndrome were excluded.
Outcomes of interest and data extraction
Data from the included studies were extracted independently by two reviewers. Any conflict was discussed in person until complete agreement was reached.
The data extracted included: author, year of publication, study period, type and intent, participant number (cases and controls) and their demographics, type, prevalence and concentrations of haemostatic mediators studied, and the relationship between mediators and non-thrombotic CVD.
Bias assessment
Case-control and cohort studies were assessed using the Newcastle-Ottawa Quality Assessment Scores (Wells et al, 2011) . RCTs were assessed using the Cochrane Risk of Bias Tool. Risk of bias across studies was not performed as a meta-analysis was not planned.
Role of the funding source
There was no funding provided for this study.
Results
Selected studies
The literature search identified 759 studies, of which 15 (Ibbotson et al, 1995; Ribeaudeau et al, 1999; Blomgren et al, 2001; Hafner et al, 2001; Jebeleanu & Procopciuc, 2001; Fink et al, 2002 Fink et al, , 2003 Gemmati et al, 2004; Yasim et al, 2008; Darvall et al, 2009 Darvall et al, , 2010 Cushman et al, 2010; Zutt et al, 2011; Calistru et al, 2012; de Franciscis et al, 2015) were selected (Fig 2) . Risk of bias assessment found that six studies were considered 'good' (40Á0%), two studies considered 'fair' (13Á3%) and seven studies were considered 'poor' (46Á7%) according to the Agency for Healthcare Research and Quality (AHRQ) standards (Higgins et al, 2011) . Data from these studies is summarised in Table IV .
Study designs and population
Twelve of the studies were case-control studies (Ribeaudeau et al, 1999; Blomgren et al, 2001; Hafner et al, 2001; Jebeleanu & Procopciuc, 2001; Fink et al, 2002; Gemmati et al, 2004; Yasim et al, 2008; Darvall et al, 2009 Darvall et al, , 2010 Cushman et al, 2010; Zutt et al, 2011; Calistru et al, 2012) , two were cohort studies (Fink et al, 2003; de Franciscis et al, 2015) and one was a RCT (Ibbotson et al, 1995) . The 15 studies included 916 non-thrombotic CVD patients (range 20-308) and 1261 (range 10-346) controls. Notably, two studies did not include healthy participants: one compared hyperhomocysteinaemia (Hhcy) patients from Hong Kong (HK) and the United Kingdom (UK) (Darvall et al, 2010) while the other compared Hhcy against non-Hhcy patients (de Franciscis et al, 2015) .
Study objectives
Most studies observed several thrombophilias. Factor V Leiden (FVL), protein C (PC) or protein S (PS) deficiency, prothrombin (PT) variants, antithrombin (AT) deficiency, methylenetetrahydrofolate reductase (MTHFR) variants and related Hhcy and lupus anticoagulant (LA) were the most commonly studied. Other factors included anticardiolipin or antiphospholipid antibodies (ACLAb/APA), factors IX, XI and XIII, von Willebrand factor (VWF), plasminogen activator inhibitor-1 (PAI-1, also termed SERPINE1), tissue plasminogen activator (tPA) and lipoprotein(a).
Nine studies noted the presence of thrombophilias in CVU (Ibbotson et al, 1995; Ribeaudeau et al, 1999; Hafner et al, 2001; Jebeleanu & Procopciuc, 2001; Fink et al, 2002 ; Zutt et al, 2011; Calistru et al, 2012; de Franciscis et al, 2015) ; only four studies covered multiple CVD severities (Blomgren et al, 2001; Darvall et al, 2009 Darvall et al, , 2010 Cushman et al, 2010) , one study observed VV (Yasim et al, 2008) while one study focused on C 4 disease (Fink et al, 2003) .
Study findings
Studies found a direct relationship between common thrombophilias and non-thrombotic CVD, with cases having higher prevalence and greater alteration in haemostatic factor concentration than controls. Multiple concomitant thrombophilias were more likely to be seen in patients with early-onset CVU (<50 years old) compared to later-onset (≥50 years old) (Calistru et al, 2012) , in cases compared to controls (Darvall et al, 2009 ) and in UK patients compared to HK Chinese patients (Darvall et al, 2010) . Finally, targeting these haemostatic factors showed promise in improving CVD treatment, with ulcer healing rates improved with both aspirin (Ibbotson et al, 1995) and folic acid (de Franciscis et al, 2015) .
The relationships between non-thrombotic CVD and individual haemostatic factors are discussed below.
Coagulation factor abnormalities. FVL (F5 R506Q) is the commonest inherited thrombophilia (Kujovich, 2011) and was described in five studies (Ribeaudeau et al, 1999; Hafner et al, 2001; Darvall et al, 2009; Cushman et al, 2010; Calistru et al, 2012) . Calistru et al (2012) found a non-significant increased FVL prevalence in early-onset CVU compared to later-onset patients. When adjusted for age, gender and race, Cushman et al (2010) found a non-significant odds ratio (OR) for CVD of 1Á2 (95% confidence interval [CI], 0Á5-2Á6) but found a greater OR on subgroup analysis of patients with trophic skin changes (OR = 2Á3, 95% CI, 0Á8-7Á1). Darvall et al (2009) showed prevalence to be equal between populations and Ribeaudeau et al (1999) found no significant difference between cases and controls. Although Hafner et al (2001) showed that the prevalence was higher in cases, the difference was not statistically significant. Pooled analysis showed a nonsignificant OR of 1Á31 (95% CI, 0Á64-2Á69) (Fig 3) .
Elevated factor VIII (FVIII) was observed in CVD patients by four studies (Ibbotson et al, 1995; Darvall et al, 2009 Darvall et al, , 2010 Cushman et al, 2010) . Cushman et al (2010) showed an OR of 1Á4 (95% CI, 0Á9-2Á1) for CVD after factoring in demographics, body mass index (BMI) and family history of CVU. CVU and VV cases were found to have a 10-fold and 3-fold prevalence of elevated FVIII respectively compared to controls (Darvall et al, 2009 ). Finally, Darvall et al (2010) showed nonsignificantly higher prevalence in UK compared to HK patients (19% vs. 14%). It must be noted that these studies defined elevated levels with cut-off concentrations of 107% (Cushman et al, 2010) , 132% (Darvall et al, 2009 ) and 150% (Darvall et al, 2010) respectively. Levels were also higher in CVU cases studied in an earlier study, where ulcer healing was accelerated with aspirin treatment (Ibbotson et al, 1995) . Because this is an acute phase reactant, raised in inflammatory and other pathological states, elevation may be a secondary phenomenon and not the initiating event for CVD pathogenesis.
Other coagulation factors were also investigated. Factors IX and XI were included in two studies (Darvall et al, 2009 (Darvall et al, , 2010 . Compared to controls, factor XI (FXI) prevalence was found to be non-significantly higher in both CVU (OR = 4Á0, 95% CI, 0Á93-42Á80) and VV cases (OR = 2Á0, 95% CI, 0Á54-9Á08); however, FXI activity levels were shown to be higher in both CVU (mean difference (MD) = 21Á4, 95% CI, 8Á54-34Á31) and VV cases (MD = 26Á67, 95% CI, 4Á21-49Á12) (Darvall et al, 2009) . Factor XIII (FXIII) was studied by Gemmati et al (2004) and, while no deficiency was shown in cases, the F13A1 V34L allele, conferring higher activity, was associated with a reduction in ulcer size (Gemmati et al, 2004) . Prothrombin mutations were studied in four studies (Jebeleanu & Procopciuc, 2001; Darvall et al, 2009; Cushman et al, 2010; Calistru et al, 2012) with focus on the F2 G20210A mutation. The relationship between this factor and CVD was weaker and the majority of studies did not identify significant differences between cases and controls. Non-significantly higher prevalence was shown in early-onset compared to late-onset CVU (Calistru et al, 2012) .
MEDLINE and Embase
Hyperhomocysteinaemia. Hhcy is a risk factor for thrombosis (Cattaneo, 1999) with elevated levels related to vitamin deficiencies or MTHFR mutations. Four studies investigated Hhcy and MTHFR mutations as potential risk factors for CVD (Darvall et al, 2009 (Darvall et al, , 2010 Calistru et al, 2012; de Franciscis et al, 2015) . Higher prevalence of Hhcy was shown in cases compared to controls (Darvall et al, 2009 ) and in UK patients when compared to HK patients (Darvall et al, 2010) . Calistru et al (2012) showed a non-significant difference in MTHFR mutations between groups. However, not all patients were tested for MTHFR mutations due to unavailability of the test at the investigation site after a specific date.
de Franciscis et al (2015) showed that administering folic acid significantly reduced plasma homocysteine. This was associated with ulcer healing improvements of almost 0Á2 cm 2 /week when compared to compression stockings alone (de Franciscis et al, 2015) .
Anticoagulation abnormalities. Antithrombin deficiency was covered in three studies, which showed no significant difference between cases and controls (Ribeaudeau et al, 1999; Darvall et al, 2009; Calistru et al, 2012) . PC and PS deficiency were studied in four papers (Ribeaudeau et al, 1999; Yasim et al, 2008; Darvall et al, 2009; Calistru et al, 2012) . Contrary to expectations, Yasim et al (2008) found a significantly higher PS level in cases than controls. All other studies showed no significant difference. The rarity of these deficiencies makes it difficult to conduct adequately powered studies.
Fibrinolysis abnormalities. Three studies observed PAI-1 in relation to CVD (Ibbotson et al, 1995; Blomgren et al, 2001; Calistru et al, 2012) . SERPINE1 (previously termed PAI1) homozygous mutations, conferring a hypofibrinolytic state, were significantly more prevalent in patients with early-onset ulcers compared to the later-onset group (Calistru et al, 2012) . Blomgren et al (2001) showed higher PAI-1 levels of 5Á6 l/ml in grade III (C 5-6 ) compared to 2Á0 and 2Á1 l/ml for grade I (C 2 ) and II (C 4 ) CVD patients, respectively, but not when compared to controls. Ibbotson et al (1995) showed higher PAI-1 concentrations in cases than controls with aspirin treatment yielding no effect. ACLAb, anticardiolipin antibody; AD;S;P, Anatomical classification deep veins, superficial veins, perforating veins; APA, antiphospholipid antibody; AS, aetiology secondary; AT, antithrombin; BMI, body mass index; CEAP, Clinical-Etiology-Anatomy-Pathophysiology; CI, confidence interval; CRP, C-reactive protein; CVD, chronic venous disorder; CVI, chronic venous insufficiency; CVU, chronic venous ulceration; DVT, deep vein thrombosis; ESR, erythrocyte sedimentation rate; FIX, factor IX; FVIII, factor VIII; FVL, factor V Leiden; FXI, factor XI; FXIII, factor XIII; Hhcy, hyperhomocysteinaemia; LA, lupus anticoagulant; OR, odds ratio; PAI-1, plasminogen activator inhibitor 1; PC, protein C; PR, pathophysiology reflux; PS, protein S; PT, prothrombin; tPA, tissue plasminogen activator; VV, varicose vein; VWF, von Willebrand factor.
Tissue plasminogen activator antigen was investigated by two studies (Blomgren et al, 2001; Yasim et al, 2008) . While both found no significant difference in tPA levels between cases and controls, Blomgren et al (2001) again showed higher tPA levels of 10Á8 lg/l in grade III compared to 6Á4 and 7Á5 lg/l in grade I and II CVD patients respectively. These studies examined tPA antigen levels, which are difficult to interpret due to complex formation with PAI-1; measuring activity levels may provide more valuable information.
Lupus-related antibodies. Three lupus-related antibodies were studied: LA, ACLAb and APA. LA prevalence in CVD was observed in two studies, with Fink et al (2002) reporting significantly higher prevalence in CVU cases than controls (59Á3% vs. 3Á2%), but contradicted by Darvall et al (2009) , who showed no significant difference. One potential explanation for this contradiction is the geographical variation of LA, with these studies reporting on Austrian and UK cohorts respectively. Additionally, while both used tests based on the Russell's Viper Venom test, these were produced by different manufacturers. Calistru et al (2012) showed no difference in relation to the age of CVU onset. A later cohort study showed that LA-positive CVD cases were more than five times more likely to develop CVU within a 4-year period (OR = 5Á25; 95% CI, 4Á5-6Á0) when compared to cases which were LA negative (Fink et al, 2003) . A pooled analysis showed a significant OR of 8Á75 (95% CI, 1Á27-60Á47), but moderate heterogeneity (I 2 = 52%) precluded any clear conclusions (Fig 4) . ACLAb prevalence was similar in cases and controls (Darvall et al, 2009 ) and in early-onset and later-onset CVU (Calistru et al, 2012) . APA prevalence was also similar between cases and controls (Ribeaudeau et al, 1999) . Anti-b 2 glycoprotein antibodies have not been studied in relation to CVD.
Other factors. In all studies investigating VWF, levels were higher in cases than controls. This was significantly raised in two studies (Yasim et al, 2008; Cushman et al, 2010) with a trend towards significance in the remaining one (Ibbotson et al, 1995) . Elevated VWF was associated with an OR of 1Á5 (95% CI, 1Á0-2Á3) for CVD after adjusting for demographics, BMI and family history of CVU (Cushman et al, 2010) . While elevated VWF is often a primary condition, it must be caveated that elevated levels could also be secondary to vessel wall damage or inflammation.
Lipoprotein(a) was studied by Zutt et al (2011) and shown to be more frequently elevated in cases than controls (48Á6% vs. 20Á2%). Although cases were older than controls, the difference remained after controlling for the effect of age.
Discussion
This systematic review has highlighted aberrations in most genetic and acquired mediators of thrombophilia in the non- thrombotic CVD population. Thrombophilia factors are more likely to be present, be present in greater numbers and concentrations altered with greater magnitude in non-thrombotic CVD cases compared to controls. This finding is strongest for commoner thrombophilia factors, such as FVIII and VWF, showing both higher prevalence in cases and significant ORs for non-thrombotic CVD if present, with weaker positive relationships shown for FVL and LA, particularly with reference to CVU. Findings, however, are inconclusive for less common thrombophilias, such as anticoagulation factor deficiency (AT, PC, PS), fibrinolytic abnormalities (tPA and PAI-1), and other thrombophilic mediators (APA, lipoprotein(a)) in relation to any severity of non-thrombotic CVD.
This study is relevant and important, with both clinical and research implications. Firstly, the results have identified patients who may be at a higher risk of developing CVD. Patients with elevated FVIII and, to a lesser extent, FVL and LA, could be considered at higher risk of CVD; healthcare professionals caring for these individuals should consider CVD as a differential diagnosis in the presence of lower limb symptoms. However, there are insufficient data to suggest routine screening for thrombophilias at this time. Secondly, patients with a concomitant thrombophilia undergoing interventions for CVD are at a higher venous thromboembolism (VTE) risk. This is particularly important in light of the lack of clear evidence regarding the administration of routine thromboprophylaxis in patients undergoing superficial venous interventions (Wittens et al, 2015) . Finally, the only cohort study included in this review (Fink et al, 2003) showed that patients were more likely to develop CVU if LA was present. Future studies should explore the clinical usefulness of thrombophilia mediators as potential biomarkers for CVU development or recurrence.
This review is, to the authors' knowledge, the first of its kind in examining the relationship between thrombophilias and non-thrombotic CVD. Two reviewers independently performed the literature search, study screening and selection, and data extraction. The review is further strengthened by the inclusion of both observational and clinical trial data, identified using a comprehensive search strategy covering multiple databases, which permitted a wide search of the existing literature. The inclusion of 12 case-control studies, two cohort studies, and one RCT that studied a variety of thrombophilic mediators in various populations, lends a degree of generalisability to our findings. This review has also provided subgroup analysis divided by mediators and CVD severity, presenting individualised relationships between specific mediators and VV, trophic skin changes and CVU. The evidence appears strongest for CVU, with frequency and severity shown to be related to coagulation (Darvall et al, 2009; Calistru et al, 2012) and fibrinolytic factors (Blomgren et al, 2001; Calistru et al, 2012) , providing clinical evidence for the microvascular and fibrin cuff theories.
This review also has limitations. First, due to the majority of studies being of case-control design, causation could not be established. This may not be crucial for primary thrombophilias as the factor aberrations are likely to be present from birth, but this may not be so for acquired thrombophilias. Second, small populations were included in the majority of studies, making it difficult to achieve sufficient numbers to reach statistical significance for less common thrombophilias. Third, genetic variants of haemostatic mediators may be present in heterozygous or homozygous states. Homozygous states confer a higher thrombotic risk than heterozygotes -FVL homozygotes have 80-times normal risk while heterozygotes only have a seven-fold risk (Cushman et al, 2004 ) -and while likely present in non-thrombotic CVD, this differential was not sufficiently explored in the included studies. Notably, PAI-1 4G/4G homozygous mutation showed a significant association with early-onset CVD (Calistru et al, 2012) . Fourth, the majority of studies failed to report on established risk factors, such as obesity and personal or family history of VTE or CVD. One study also failed to report the ages of their cases and controls (Jebeleanu & Procopciuc, 2001 ). These characteristics are clearly relevant when trying to ascertain the independent impact of thrombophilia. Fifth, studies used different definitions of healthy controls, ranging from the absence of clinical signs or symptoms (Ribeaudeau et al, 1999; Fink et al, 2002 Fink et al, , 2003 Yasim et al, 2008) to using imaging studies, such as venography (Hafner et al, 2001) or venous duplex ultrasound (Darvall et al, 2009 (Darvall et al, , 2010 Cushman et al, 2010; de Franciscis et al, 2015) . This contributed to the heterogenous risk of bias seen in the included studies, with those rated 'poor' largely failing to account for such details. Finally, the potential presence of subclinical deep vein thrombosis (DVT) may have affected the study populations because most included CVD patients if they did not have previous VTE in their medical history. This potential mediator was recognised by one study (Darvall et al, 2009) , which suggested that, as thrombophilic risk factors of CVD overlapped with those of VTE, some patients may develop postthrombotic CVD following previously unrecognised DVT.
Future studies should be of prospective design to determine if thrombophilia has a causative role. Larger cohorts are required to identify rarer thrombophilias that may affect CVD pathogenesis and to categorise genetic mutations by zygosity for comparison. This could be done using a genome wide association study, which requires a well phenotyped cohort of both patients and controls defined using objective assessment of their venous system by imaging methods. Given the evidence of high rates of false positives and negatives, diagnostic tests must be chosen carefully to minimise methodological error margins that currently exist. Targeting procoagulant factors may hold promise in the treatment of CVD and further studies should extend to previously trialled targeted therapies, including topical treatment with tissue plasminogen activator (Zeegelaar et al, 1997) and oral regimes of sulodexide, a purified glycosaminoglycan with fibrinolytic properties (Wu et al, 2016) .
Review
Thrombophilia in CVD is not a new concept -the earliest study included in this review was performed over 20 years agoand appears to be related to non-thrombotic CVD development. Given the surrounding descriptive literature and in line with previously proposed theories of CVD pathogenesis involving fibrin cuff formation and microvascular changes, thrombophilia should be revealed as a pertinent risk factor for both non-thrombotic CVD pathogenesis and deterioration in future research.
